Revenue: As of FY2026 Q2, the actual value is USD 7.2 M.

Second Quarter 2026 Sales Highlights

ImmuCell Corporation reported total product sales of $7.2 million for the three months ended June 30, 2026, representing an 11.5% increase compared to the same period in 2025. Domestic sales grew by 27.7% to $6.2 million, while international sales decreased by -38.9% to $1.0 million for the quarter. Sales of Tri-Shield First Defense® increased by 8.3% to $4.9 million, and Dual-Force® and Other Sales rose by 19.1% to $2.3 million for the quarter.

First Six Months of 2026 Sales Highlights

For the six months ended June 30, 2026, total product sales reached $17.5 million, marking a 20.9% increase over the first six months of 2025. Domestic sales for this period were $16.0 million, an increase of 32.5%, while international sales were $1.6 million, a decrease of -35.7%. Tri-Shield First Defense® sales for the six months totaled $12.8 million, an increase of 25.1%, and Dual-Force® and Other Sales amounted to $4.8 million, growing by 10.9%.

Operational Insights

ImmuCell Corporation’s growth in the second quarter was significant despite a challenging comparison with the second quarter of 2025, which included substantial sales from distributors replenishing inventory after an extended period of backorders. Commercial efforts during the quarter focused on year-round dairy customers, a more price-sensitive segment, which contributed to the growth of Dual-Force® and Tri-Shield®. The expansion of the commercial team is also contributing to increased customer acquisitions in this segment.

Outlook

Management anticipates discussing revenue drivers and complete financial results during a conference call scheduled for Friday, August 14, 2026. ImmuCell Corporation believes that end-customer demand for its products remains strong, particularly in Canada, despite recent international sales declines.